Brief: Expres2ion Biotech Highlights BIO-002 Clinical Data
22/04/2026 10:09
April 22 (Reuters) - ExpreS2ion Biotech Holding AB EXPRS2.ST: EXPRES2ION BIOTECH HIGHLIGHTS BIO-002 CLINICAL DATA SUPPORTING PLATFORM VALIDATION, SCALABILITY AND PARTNERED DEVELOPMENT MODEL DATA DEMONSTRATE CONSISTENT ANTIBODY RESPONSES WITH FUNCTIONAL ACTIVITY AGAINST MALARIA PARASITE Source text: (Full Story) Further company coverage: EXPRS2.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on ExpreS2ion Biotech Holding AB
See all newsBrief: Expres2ion Biotech To Raise SEK 19.3 Million From Warrants And Share Issue
Brief: ExpreS2ion Reports Q2 Loss Of SEK 9.7 Million
Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
Brief: Expres2ion Biotech Holding Q1 2026 Operating Income SEK 6.87 Mln
Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations